On July 10, 2009, the FDA approved Effient (prasugrel) for the reduction of thrombotic cardiovascular events in patients with acute coronary syndromes undergoing percutaneous coronary intervention. However, the approval has surprised many physicians as prasugrel has had a tortuous clinical development program, with important questions raised over its clinical benefits and the trial design.
With Japan poised to receive its first biosimilar and the US moving ever closer to the establishment of an approval pathway, the biosimilars market is set for imminent expansion. Given the size of the US market and the generic erosion which characterizes it, the sector is an attractive prospect for large and established pharmaceutical companies looking to succeed in the biosimilars sector.
Drug repositioning strategies: a different approach to innovation
With increased investment in R&D largely failing to fill drug development pipelines, the pharma industry is looking to get more bang for its R&D buck by generating some return out of failed drug candidates and extra return out of others. Drug re-positioning has become a key strategy for pharmaceutical groups, and according to Datamonitor, this approach is set to become more frequently employed
Healthcare Brands International announces the acquisition of Antula Holdings AB
Healthcare Brands International (HBI) announces the completion of a
major step towards its goal of building a new international Over-the-Counter
(OTC) healthcare business with the acquisition of Antula Holdings AB, the
privately-owned Scandinavian OTC healthcare business, and its subsidiaries.
Be Recognized
as Sponsor to FarmavitaR+ Regulatory Affairs Network
FarmavitaR+ (http://www.farmavitar.net) is the online network for regulatory affairs profesionals. Sponsorship of FarmavitaR+ allows your
organization to maximize its presence in front of a target audience of regulatory affairs executives in the worldwide pharmaceutical and biopharma sector.
Croatia and FYR Macedonia join Competitiveness and Innovation Programme
CORDIS, 2007-10-19:Croatia and the Former Yugoslav Republic of
Macedonia have joined the EU's Competitiveness and Innovation Programme
(CIP), under which the European Commission promotes innovation,
entrepreneurship and growth in small and medium-sized enterprises
(SMEs).
The Farmavita.Net has profiled itself to be the top service agent in pharmaceutical business development and licensing in central-east and south-east Europe. At this moment, members at Farmavita.Net are offering license-out for few hundreds health products/technologies. Also, members of Farmavita.Net are looking to license-in number of products/technologies.
In collaboration with Regulanet network of regulatory affairs consultants throughout Europe and USA, we keep
daily contacts and communication with National Agencies for Medicines
and Medical Devices. Beside regulatory we also maintain understanding of the business, scientific and technical background of products.
FarmavitaR+ Journal 
